Non-Hodgkin Lymphoma

A simplified geriatric assessment offers a validated objective tool to assess fitness status and should be considered the new Elderly Prognostic Index standard to predict overall survival in older patients with diffuse large B-cell lymphoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of single-agent duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia following at least 2 prior therapies, and follicular lymphoma that is refractory to at least 2 prior systemic treatments.

CAR T-cell therapies are now incorporated into National Comprehensive Cancer Network guidelines as a recommended third-line strategy in this setting, with the most recent addition being lisocabtagene maraleucel.

Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

Sattva Neelapu, MD, discusses CAR T-cell products that have been approved by the FDA for different subtypes of lymphoma.

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies and the challenges with using a 5-drug regimen.

Ibrutinib as a frontline treatment led to sustained efficacy and impressive 4-year progression-free and overall survival rates in patients with chronic lymphocytic leukemia who have TP53 aberrations.

Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.

The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.

The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory indolent follicular lymphoma after 2 or more lines of systemic therapy.